Table 5. First and best responses achieved during alectinib treatment.

First response, n (%)	Patients 111 (100)
Complete response (CR)	2 (1.8)
Partial response (PR)	55 (49.5)
Stable disease (SD)	29 (26.1)
Progressive disease (PD)	15 (13.5)
Not evaluable (NE)	10 (9)
Time to first response (months)	Valid N (107)
Mean (SD; 95% CI)	2.6 (2.1; 2.1–3)
Median (IQR; min, max)	2.4 (1.5–3; 0, 14.6)
Best response, n (%)	110 (100)
Complete response (CR)	5 (4.5)
Partial response (PR)	55 (50)
Stable disease (SD)	28 (25.5)
Progressive disease (PD)	14 (12.7)
Not evaluable	8 (7.3)
Objective response rate (ORR), n (%)	110 (100)
CR + PR	60 (54.5)
Disease control rate (DCR), n (%)	110 (100)
CR + PR + SD	88 (80)
Time to best response (months)	Valid N (106)
Mean (SD; 95% CI)	4.8 (5.1; 3.8–5.8)
Median (IQR; Min, max))	2.8 (1.9–5.9; 0.1, 21.2)
Duration of response (DOR, months)	Valid N (37)
Mean (SD; 95% CI)	7.5 (5.8; 5.6–9.4)
Median (IQR; min, max)	5.3 (3.4–9.2; 0.2, 22.4)

Abbreviations: CI: confidence interval; IQR: interquartile range (25–75); min: minimum; max: maximum; SD: standard deviation.